Rakesh K. Goel

501 Smyth Road
Ottawa, ON K1H8L6, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Corrigendum to "A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site" [Eur J Cancer (2026) 239 116709].

Corrigendum to "A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site" [Eur J Cancer (2026) 239 116709].

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 17, 2026

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2025.

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2025.

Journal: Current oncology (Toronto, Ont.)

Published: February 22, 2026

A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site.

A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 11, 2025

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2024.

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2024.

Journal: Current oncology (Toronto, Ont.)

Published: February 15, 2025

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019.

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019.

Journal: Current oncology (Toronto, Ont.)

Published: April 30, 2021

Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.

Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.

Journal: JAMA oncology

Published: September 06, 2019

Phenytoin Toxicity During Neoadjuvant Concurrent Capecitabine and Radiation Therapy for Rectal Adenocarcinoma: Case Report of a Drug Interaction.

Phenytoin Toxicity During Neoadjuvant Concurrent Capecitabine and Radiation Therapy for Rectal Adenocarcinoma: Case Report of a Drug Interaction.

Journal: Cureus

Published: January 31, 2019

A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Journal: Investigational new drugs

Published: March 09, 2018

Variable Endoscopist performance in proximal and distal adenoma detection during colonoscopy: a retrospective cohort study.

Variable Endoscopist performance in proximal and distal adenoma detection during colonoscopy: a retrospective cohort study.

Journal: BMC gastroenterology

Published: July 01, 2017

A Phase I Study of Irinotecan, Capecitabine (Xeloda), and Oxaliplatin in Patients With Advanced Colorectal Cancer.

A Phase I Study of Irinotecan, Capecitabine (Xeloda), and Oxaliplatin in Patients With Advanced Colorectal Cancer.

Journal: Clinical colorectal cancer

Published: April 05, 2017

Increased prevalence of colonic adenomas in patients with cystic fibrosis.

Increased prevalence of colonic adenomas in patients with cystic fibrosis.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: March 30, 2017

Showing 1-11 of 11

Last Updated: 09/26/2026